Skip Navigation

Annals of Oncology 2007 18(Supplement 12):xii15-xii20; doi:10.1093/annonc/mdm534
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pusztai, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pusztai, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

symposium articles

Markers predicting clinical benefit in breast cancer from microtubule-targeting agents

L. Pusztai*

Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA

* Correspondence to: Dr L. Pusztai, Department of Breast Medical Oncology, Unit 1354, UT MD Anderson Cancer Center, PO Box 30 1439, Houston, TX 77230-1439, USA. Tel: +1-713-792-2817; E-mail: lpusztai{at}mdanderson.org

Taxanes (e.g. paclitaxel, docetaxel) and epothilones (e.g. ixabepilone) are microtubule-targeting agents, which disrupt cellular processes and induce apoptosis. Although their mechanisms of action are similar, clinical data in breast cancer patients support at least partial non-cross resistance between the classes, and even between individual compounds. Several biomarkers might contribute to the identification of patient groups likely to derive benefit from one class of microtubule-targeting agent or even one agent. Overexpression of P-glycoprotein is associated with resistance to taxanes, but not ixabepilone, in vitro; its role in vivo remains unclear. Mutations in β-tubulin linked to resistance to taxanes but not epothilones are observed in vitro; somatic mutations of β-tubulin appear rare clinically. Overexpression of the βIII-tubulin isoform is associated with taxane resistance in cell lines; some clinical studies support a relationship between poor response to taxanes and overexpression of βIII-tubulin. βIII-tubulin overexpression seems not to affect sensitivity to ixabepilone [1]. Estrogen receptor negativity, low expression of microtubule-associated protein tau, and perhaps HER2 amplification may define a subset of patients with higher than average sensitivity to paclitaxel. Large scale pharmacogenomic analysis has identified molecular markers potentially capable of distinguishing patients with differential sensitivity to paclitaxel and ixabepilone. These markers require validation in clinical trials.

Key words: breast cancer, epothilone, ixabepilone, taxane, microtubule-targeting agents, tubulin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
C. Hudis and C. Dang
The Taxane Limbo: How Low Can We Go?
J Natl Cancer Inst, June 4, 2008; 100(11): 761 - 763.
[Full Text] [PDF]

Home page
 The OncologistHome page
L. Pusztai
Current Status of Prognostic Profiling in Breast Cancer
Oncologist, April 1, 2008; 13(4): 350 - 360.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.